Monitor tumor burden with circulating tumor DNA

Cancer Biology and Therapy

Volumn 14, Issue 8, 2013, Pages 697-698

  Figg II, William D ^a   Reid, Jim ^a  

^a Woodberry Forest School   (United States)

Author keywords

Biomarkers; Breast cancer; Circulating DNA; Clinical trials; Disease progression; Sequencing; Somatic mutations

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA; DNA FRAGMENT; PROSTATE SPECIFIC ANTIGEN;

BREAST CANCER; BREAST METASTASIS; CIRCULATING TUMOR CELL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; OVARY CANCER; POINT MUTATION; SHORT SURVEY; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR VOLUME;

BIOMARKERS; BREAST CANCER; CIRCULATING DNA; CLINICAL TRIALS; DISEASE PROGRESSION; SEQUENCING; SOMATIC MUTATIONS;

BREAST NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; HUMANS; NEOPLASTIC CELLS, CIRCULATING; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84881462896     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25361     Document Type: Short Survey

References (8)

1. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14:5967-76; PMID:18829475; http://dx.doi.org/10.1158/1078-0432.CCR-07-4535
2. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24:971-83; PMID:16900146; http://dx.doi.org/10.1038/nbt1235
3. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101:374-83; PMID:19276453; http://dx.doi. org/10.1093/jnci/djp001
4. Bates SE, Longo DL. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 1985; 12:163-207; PMID:2416441; http://dx.doi.org/10.1016/0305-7372(85)90037-4
5. Ligthart ST, Coumans FA, Attard G, Cassidy AM, de Bono JS, Terstappen LW. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 2011; 6:e27419; PMID:22087312; http://dx.doi. org/10.1371/journal.pone.0027419
6. Dixon SC, Horti J, Guo Y, Reed E, Figg WD. Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nat Biotechnol 1998; 16:91-4; PMID:9447601; http://dx.doi. org/10.1038/nbt0198-91
7. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635:105-17; PMID:17257890; http://dx.doi.org/10. 1016/j. mrrev.2006.11.002
8. Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-209; PMID:23484797; http://dx.doi.org/10.1056/NEJMoa1213261